A novel oHSV-1 targeting telomerase reverse transcriptasepositive cancer cells via tumor-specific promoters regulating the expression of ICP4

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20345-20355

  Zhang, Wen ^a   Ge, Keli ^a   Zhao, Qian ^a   Zhuang, Xiufen ^a   Deng, Zhenling ^a   Liu, Lingling ^a   Li, Jie ^a   Zhang, Yu ^a   Dong, Ying ^a   Zhang, Youhui ^a   Zhang, Shuren ^a   Liu, Binlei ^a,b  

^a CANCER HOSPITAL   (China)

^b HUBEI UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

HTERT; ICP4; Oncolytic HSV 1; Oncolytic virotherapy; Tumor specific

Indexed keywords

IMMEDIATE EARLY PROTEIN; MESSENGER RNA; ONCOLYTIC HERPES SIMPLEX VIRUS 1; ONCOLYTIC HERPES VIRUS; PROTEIN ICP4; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CARCINOGEN; HERPES SIMPLEX VIRUS, TYPE 1 PROTEIN ICP4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD CELL; CANCER CELL; CANCER CELL CULTURE; CANCER CELL LINE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HERPES SIMPLEX VIRUS 1; METABOLISM; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOGENS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940199056     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3884     Document Type: Article

References (44)

1. Stanford MM, Bell JC, Vähä-Koskela MJ. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev. 2010; 21:177-183.
2. Quetglas JI, John LB, Kershaw MH, Alvarez-Vallina L, Melero I, Darcy PK, Smerdou C. Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology. 2012; 1:1344-1354.
3. Hemminki A, Oksanen M, Merisalo-Soikkeli M. Oncolytic virotherapy trials-letter. Clin Cancer Res. 2013; 19:4541-4542.
4. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007; 28:326-333.
5. Sze DY, Reid TR, Rose SC. Oncolytic virotherapy. J Vasc Interv Radiol. 2013; 24:1115-1122.
6. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2013; 30:658-670.
7. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007; 4:101-117.
8. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013; 2:e24612.
9. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009; 9:505-517.
10. Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 2009; 17:1125-1135.
11. Miao L, Fraefel C, Sia KC, Newman JP, Mohamed-Bashir SA, Ng WH, Lam PY. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy. Br J Cancer. 2014; 110:94-106.
12. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10:292-303.
13. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2014; 3:e28694.
14. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets. 2007; 7:181-189.
15. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985; 56:558-570.
16. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997; 71:5124-5132.
17. Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S, Nakamura H, Donahue JM, Tanabe KK. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg. 2002; 236:502-512.
18. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. 2006; 66:10127-10135.
19. Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Osakada M, Hirano N, Sasaki Y, Yoden T, Awata N, Araki N, Tatsuta M, Miyatake SI, Takahashi K. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001; 61:3969-3977.
20. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res. 2004; 10:285-292.
21. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33:787-791.
22. Shampay J, Blackburn EH. Generation of telomere-length heterogeneity in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 1998; 85:534-538.
23. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I, Robinson MO. A mammalian telomerase-associated protein. Science. 1997; 275:973-977.
24. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J. The RNA component of human telomerase. Science. 1995; 269:1236-1241.
25. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997; 277:955-959.
26. Sundin T, Hentosh P. InTERTesting association between telomerase, mTOR and phytochemicals. Expert Rev Mol Med. 2012; 14:e8.
27. Mocellin S, Verdi D, Pooley KA, Landi MT, Egan KM, Baird DM, Prescott J, De Vivo I, Nitti D. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst. 2012; 104:840-854.
28. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999; 13:2388-2399.
29. Glukhov AI, Svinareva LV, Severin SE, Shvets VI. Telomerase inhibitors as novel anitumour durgs. Applied Biochemistry and Microbiology. 2011; 47:655-660.
30. Zhuang X, Zhang W, Chen Y, Han X, Li J, Zhang Y, Zhang Y, Zhang S, Liu B. Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer. 2012; 12:549.
31. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008; 6:529-540.
32. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev. 2009; 61:554-571.
33. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009; 17:199-207.
34. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006; 12:6737-6747.
35. Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008; 30:1045-1051.
36. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7:867-874.
37. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997; 71:5124-5132.
38. Pritchard SM, Cunha CW, Nicola AV. Analysis of herpes simplex virion tegument ICP4 derived from infected cells and ICP4-expressing cells. PLoS One. 2013; 8:e70889.
39. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985; 56:558-570.
40. Longo SL, Griffith C, Glass A, Shillitoe EJ, Post DE. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther. 2011; 18:123-134.
41. Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, Li X, Li H, You C. The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis. Tumour Biol. 2014; 35:903-916.
42. Deniz H, Karakök M, Yagci F, Güldür ME. Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol. 2010; 42:103-107.
43. Murofushi Y, Nagano S, Kamizono J, Takahashi T, Fujiwara H, Komiya S, Matsuishi T, Kosai K. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. Int J Oncol. 2006; 29:681-688.
44. Yang CT, Song J, Bu X, Cong YS, Bacchetti S, Rennie P, Jia WW. Herpes simplex virus type-1 infection upregulates cellular promoters and telomerase activity in both tumor and nontumor human cells. Gene Ther. 2003; 10:1494-1502.